Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Sullivan & Worcester represented Truliant Consulting, a leading pharmacovigilance, risk management, and regulatory compliance advisory firm, in connection with its acquisition by ELIQUENT Life Sciences. The strategic acquisition reinforces ELIQUENT’s position as a premier provider of end-to-end support for every stage of the product lifecycle.

“Since our founding, Truliant has delivered high-impact pharmacovigilance and risk management consulting to clients worldwide. Joining ELIQUENT Life Sciences marks an exciting new chapter – one where we will expand our pharmacovigilance expertise within a team that brings complementary strengths. We are fully aligned with ELIQUENT’s vision and look forward to driving innovation through this collaboration,” said Jamie Portnoff, CEO and Co-Founder, Truliant Consulting.

The Sullivan team advising Truliant was led by Scott Kaufman and Lewis Greenwald, and included Amit Shoval, Eric Rietveld, Erika Todd, Amy Sheridan, David Guadagnoli, Michael Palmisciano and Nathan Kosik-Desmond.

Resources